natgillin/translations-raw huggingface dataset:
Patients with chronic wide-angle glaucoma may be treated with Levodopa/Carbidopa/Entacapone Orion with caution, provided the intra-ocular pressure is well controlled and the patient is monitored carefully for changes in intra-ocular pressure.
Bolniki s kroničnim glavkomom odprtega zakotja se ob primerni previdnosti lahko zdravijo z zdravilom Levodopa/Carbidopa/Entacapone Orion, pod pogojem, da je intraokularni tlak dobro obvladovan in da bolnika skrbno spremljamo, če bi se pojavile spremembe v intraokularnem tlaku.
Patients with chronic wide-angle glaucoma may be treated with Stalevo with caution, provided the intra-ocular pressure is well controlled and the patient is monitored carefully for changes in intra- ocular pressure.
Bolniki s kroničnim glavkomom odprtega zakotja se ob primerni previdnosti lahko zdravijo z zdravilom Stalevo, pod pogojem, da je intraokularni tlak dobro obvladovan in da bolnika skrbno spremljamo, če bi se pojavile spremembe v intraokularnem tlaku.
Patients with chronic wide-angle glaucoma may be treated with Stalevo with caution, provided the intra-ocular pressure is well controlled and the patient is monitored carefully for changes in intra-ocular pressure.
Bolniki s kroničnim glavkomom odprtega zakotja se ob primerni previdnosti lahko zdravijo z zdravilom Stalevo, pod pogojem, da je intraokularni tlak dobro obvladovan in da bolnika skrbno spremljamo, če bi se pojavile spremembe v intraokularnem tlaku.
Patients with cirrhosis
bolniki brez ciroze
Patients with cirrhosis N = 103
Bolniki s cirozo N = 103
Patients with CKD may develop low levels of fat-soluble vitamins A, D, E and K, depending on dietary intake and the severity of their disease.
Pri bolnikih s kronično boleznijo ledvic (KBL) se lahko pojavijo nizke ravni v maščobi topljivih vitaminov A, D, E in K, odvisno od dietnega vnosa in resnosti bolezni.
Patients with CKD may develop low levels of fat-soluble vitamins A, D, E and K, depending on dietary intake and the severity of their disease.
Pri bolnikih s kronično boleznijo ledvic (KBČ) se lahko pojavijo nizke ravni v maščobi topljivih vitaminov A, D, E in K, odvisno od dietnega vnosa in resnosti bolezni.
Patients with class III disease and those with PAH caused by connective tissue disease gained a greater benefit from the 10 mg dose than from the 5 mg dose.
Bolniki z boleznijo funkcijskega razreda III in bolniki s pljučno arterijsko hipertenzijo, ki je posledica bolezni vezivnega tkiva, so imeli več koristi pri uporabi 10-miligramskega kot 5-miligramskega odmerka.
Patients with CLcr  20 ml/min do not require a dose adjustment, see section 5.2.
Bolnikom s CLcr  20 ml/min odmerka ni treba prilagajati; glejte poglavje 5.2.
Patients with CLcr  20 ml/min do not require a dose adjustment, see section 5.2. In paediatric patients with renal dysfunction who are undergoing dialysis it is recommended that following each dialysis treatment patients receive an additional dose of Viramune oral suspension or immediate-release tablets representing 50 % of the recommended daily dose of Viramune oral suspension or immediate-release tablets which would help offset the effects of dialysis on nevirapine clearance.
Bolnikom s CLcr ≥ 20 ml/min odmerka ni treba prilagajati; glejte poglavje 5.2. Pri otrocih z ledvično disfunkcijo, ki se zdravijo z dializo, priporočajo po vsaki dializi dodaten odmerek zdravila Viramune peroralna suspenzija ali Viramune tablete s takojšnjim sproščanjem, in sicer 50 % priporočenega dnevnega odmerka peroralne suspenzije ali tablet s takojšnjim sproščanjem, kar pomaga izničiti učinek dialize na nevirapinov očistek.
Patients with CLcr  20 ml/min do not require a dose adjustment, see section 5.2. In paediatric patients with renal dysfunction who are undergoing dialysis it is recommended that following each dialysis treatment patients receive an additional dose of Viramune oral suspension or immediate-release tablets representing 50% of the recommended daily dose of Viramune oral suspension or immediate-release tablets which would help offset the effects of dialysis on nevirapine clearance.
Bolnikom s CLcr ≥ 20 ml/min odmerka ni treba prilagajati; glejte poglavje 5.2. Pri otrocih z ledvično disfunkcijo, ki se zdravijo z dializo, priporočajo po vsaki dializi dodaten odmerek zdravila Viramune peroralna suspenzija ali Viramune tablete s takojšnjim sproščanjem, in sicer 50 % priporočenega dnevnega odmerka peroralne suspenzije ali tablet s takojšnjim sproščanjem, kar pomaga izničiti učinek dialize na nevirapinov očistek.
Patients with clinically important disruptions to the blood-brain barrier (e.g. primary brain malignancies, CNS metastases or other inflammatory conditions, active multiple sclerosis, advanced Alzheimer’s disease etc.) were not included in clinical studies and may be at risk for naloxegol entry into the CNS.
Bolniki s klinično pomembno prizadetostjo krvno-možganske pregrade (npr. s primarnimi malignimi boleznimi možganov, metastazami v osrednjem živčevju ali drugimi vnetnimi stanji, aktivno multiplo sklerozo, napredovalo Alzheimerjevo boleznijo itn.) niso bili vključeni v klinične študije in jih lahko ogroža prehajanje naloksegola v osrednje živčevje.
Patients with clinically significant aortic and mitral valve disease
bolniki s klinično pomembno okvaro aortne in mitralne zaklopke,
Patients with Clinically Significant Response (%)
Bolniki s klinično pomembnim odzivom (%)
Patients with CLL who received at least one prior therapy
Bolniki s KLL, ki so prej prejeli vsaj eno vrsto zdravljenja
Patients with combined mixed dyslipidaemia have high blood levels of ‘bad’ LDL cholesterol and triglycerides (a type of fat), and low levels of ‘good’ HDL cholesterol.
Bolniki s kombinirano mešano dislipidemijo imajo v krvi visoke vrednosti "slabega" LDL holesterola in trigliceridov (vrsta maščobe) in nizke vrednosti "dobrega" HDL holesterola.
Patients with compensated cirrhos is
Bolniki s kompenzirano cirozo
Patients with compensated cirrhosis and/or prior treatment failure
Bolniki s kompenzirano cirozo in/ali predhodno neuspešnim zdravljenjem
patients with complete absence of activity of the dihydropyrimidine dehydrogenase enzyme;
bolnikih s popolnim pomanjkanjem dejavnosti encima dihidropirimidin dehidrogenaze;
Patients with concomitant administration of medicinal products that may increase the risk of bleeding (e.g. non-steroidal anti-inflammatory drugs (NSAIDs), oral anticoagulants and/or fibrinolytics) within 24 hours of Possia dosing.
Bolniki, sočasno zdravljeni z zdravili, ki lahko povečajo tveganje krvavitev (npr. nesteroidna protivnetna zdravila (NSAID), peroralni antikoagulansi in/ali fibrinolitiki) v 24 urah od uporabe zdravila Possia.
Patients with concomitant administration of medicinal products that may increase the risk of bleeding (e.g. non-steroidal anti-inflammatory drugs (NSAIDs), oral anticoagulants and/or fibrinolytics) within 24 hours of ticagrelor dosing.
Bolniki, sočasno zdravljeni z zdravili, ki lahko povečajo tveganje krvavitev (npr. nesteroidna protivnetna zdravila (NSAID), peroralni antikoagulanti in/ali fibrinolitiki) v 24 urah od uporabe ticagrelorja.
Patients with concomitant diseases, or who use medicinal products which have a potential for undesirable effects on the kidney, should be reviewed regularly in line with good medical practice during treatment.
Bolnike, ki imajo sočasno še druge bolezni ali jemljejo zdravila z možnimi neželenimi učinki za ledvice, je treba med zdravljenjem redno spremljati v skladu z dobro medicinsko prakso.
Patients with concomitant diseases, or who use medicinal products which have potential for undesirable effects on the kidney, should be reviewed regularly in line with good medical practice during treatment.
Bolnike, ki imajo sočasno še druge bolezni ali jemljejo zdravila z možnimi neželenimi učinki za ledvice, je treba med zdravljenjem redno spremljati v skladu z dobro zdravniško prakso.
Patients with concomitant treatment of pravastatin, rosuvastatin or fluvastatin should be carefully monitored for signs and symptoms of myopathy and rhabdomyolysis. (See sections 4.3 and 4.5).
Bolnike, ki se sočasno zdravijo s pravastatinom, rosuvastatinom ali fluvastatinom je treba natančno nadzirati glede znakov in simptomov miopatije in rabdomiolize (glejte poglavji 4.3 in 4.5).
Patients with congestive heart failure (CHF) have been identified as a population at higher risk for hypotension. (See section 4.8.)
Ugotovili so, da je pri bolnikih s kongestivnim srčnim popuščanjem tveganje za hipotenzijo večje (glejte poglavje 4.8).
Patients with COPD and patients who are heavy smokers may have a higher risk of developing cancer with Flixabi treatment.
Bolniki s KOPB in tisti, ki veliko kadijo, imajo lahko povečano tveganje za nastanek raka pri zdravljenju z zdravilom Flixabi.
Patients with COPD and patients who are heavy smokers may have a higher risk of developing cancer with Inflectra treatment.
Bolniki s KOPB in tisti, ki so težki kadilci, imajo lahko povečano tveganje za nastanek raka pri zdravljenju z zdravilom Inflectra.
Patients with COPD and patients who are heavy smokers may have a higher risk of developing cancer with Remicade treatment.
Bolniki s KOPB in tisti, ki veliko kadijo, imajo lahko povečano tveganje za nastanek raka pri zdravljenju z zdravilom Remicade.
Patients with COPD and patients who are heavy smokers may have a higher risk of developing cancer with Remsima treatment.
Bolniki s KOPB in tisti, ki veliko kadijo, imajo lahko povečano tveganje za nastanek raka pri zdravljenju z zdravilom Remsima.
Patients with coronary atherosclerosis were included who required PCI for stable angina (58%), non-ST-segment elevation acute coronary syndrome (NSTE-ACS) (26%), or ST-elevation myocardial infraction (STEMI) (16%).
Vključeni so bili bolniki s koronarno aterosklerozo, pri katerih je bila PKI potrebna zaradi stabilne angine pektoris (58 %), akutnega koronarnega sindroma brez elevacije spojnice ST (NSTE-ACS, non-ST-segment elevation acute coronary syndrome) (26 %) ali miokardnega infarkta z elevacijo spojnice ST (STEMI, ST-elevation myocardial infraction) (16 %).
Patients with CrCl between 30 mL/min and 60 mL/min:
Bolniki s CrCl med 30 ml/min in 60 ml/min:
Patients with creatinine clearance >60 ml/min have been included in efficacy/safety studies of topotecan.
Bolniki z očistkom kreatinina >60 mL/min so bili vključeni v raziskavo o učinkovitosti/varnosti topotekana.
Patients with Crohn’s disease, who have not shown a response may benefit from a dose of Entyvio at Week 10 (see section 4.4).
Bolnikom s Crohnovo boleznijo brez odziva na zdravljenje morda lahko koristi odmerek zdravila Entyvio v 10. tednu (glejte poglavje 4.4).
Patients with CSU: The effects of demographic characteristics and other factors on omalizumab exposure were evaluated based on population pharmacokinetics.
Bolniki s kronično spontano urtikarijo: Vpliv demografskih značilnosti in drugih dejavnikov na izpostavljenost omalizumabu so ocenjevali s pomočjo populacijske farmakokinetike.
patients with current concomitant therapy with oral anticoagulants (e.g. warfarin sodium)
bolniki, ki se sočasno zdravijo s peroralnimi antikoagulanti (npr. natrijev varfarinat),
Patients with current severe depression and/or suicidal ideation (see sections 4.4 and 4.8).
Bolniki s hudimi depresivnimi motnjami in/ali samomorilnimi mislimi (glejte poglavji 4.4 in 4.8).
Patients with current severe depression and/or suicidal ideation (see sections 4.4 and 4.8).
Bolniki s hudo depresijo in/ali samomorilnimi mislimi (glejte poglavji 4.4 in 4.8).
Patients with current severe depression and/or suicidal ideation (see sections 4.4 and 4.8).
Pri bolnikih s prisotno hudo depresijo in/ali samomorilnimi nagnjenji (glejte poglavji 4.4 in 4.8).
Patients with cystinosis taking immediate-release cysteamine bitartrate may be transferred to a total daily dose of PROCYSBI equal to their previous total daily dose of immediate-release cysteamine bitartrate.
Bolniki s cistinozo, ki jemljejo cisteaminijev bitartrat s takojšnjim sproščanjem, lahko preidejo na skupni dnevni odmerek zdravila PROCYSBI, ki ustreza predhodnemu skupnemu dnevnemu odmerku cisteaminijevega bitartrata s takojšnjim sproščanjem.
Patients with decompensated liver disease: in study 048, 191 patients with HBeAg positive or negative chronic HBV infection and evidence of hepatic decompensation, defined as a CTP score of 7 or higher, received entecavir 1 mg once daily or adefovir dipivoxil 10 mg once daily.
Bolniki z dekompenzirano boleznijo jeter: v študiji 048 je 191 HBeAg pozitivnih ali negativnih bolnikov s kronično okužbo z virusom HBV in z znaki dekompenzacije jeter, opredeljene z oceno 7 ali večjo po CTP lestvici, prejemalo entekavir v odmerku 1 mg enkrat na dan ali adefovirdipivoksil v odmerku 10 mg enkrat na dan.
Patients with decompensated liver disease: The safety profile of tenofovir disoproxil fumarate in patients with decompensated liver disease was assessed in a double-blind active controlled study (GS-US-174-0108) in which adult patients received treatment with tenofovir disoproxil fumarate (n = 45) or emtricitabine plus tenofovir disoproxil fumarate (n = 45) or entecavir (n = 22) for 48 weeks.
Bolniki z dekompenzirano jetrno boleznijo: Varnostni profil dizoproksiltenofovirijevega fumarata pri bolnikih z dekompenzirano jetrno boleznijo je bil ocenjen v dvojno slepi aktivno kontrolirani študiji (GS-US-174-0108), med katero so bili odrasli bolniki 48 tednov zdravljeni z dizoproksiltenofovirijevim fumaratom (n = 45) ali z emtricitabinom in dizoproksiltenofovirijevim fumaratom (n = 45) ali z entekavirjem (n = 22).
Patients with deficient glucuronidation of bilirubin, such as those with Gilbert’s syndrome, may be at greater risk of myelosuppression when receiving therapy with ONIVYDE.
Bolniki s pomanjkljivo glukuronidacijo bilirubina, kot so bolniki z Gilbertovim sindromom, imajo med zdravljenjem z zdravilom ONIVYDE lahko večje tveganje za mielosupresijo.
Patients with dementia and Parkinson’s disease
Bolniki z demenco in Parkinsonovo boleznijo
Patients with dementia and Parkinson’s disease
Bolniki z demenco v povezavi s Parkinsonovo boleznijo
Patients with depression should be treated for at least six months to make sure that they are free of symptoms.
Bolniki z depresijo naj se zdravijo vsaj šest mesecev, da se zagotovi popolna odprava simptomov.
Patients with detectable HCV RNA at either weeks 4 or 12 receive an additional 36 weeks of peginterferon alfa and ribavirin alone for a total treatment duration of 48 weeks.
Bolniki z zaznavno koncentracijo HCV RNK v 4. ali v 12. tednu naj prejemajo samo peginterferon alfa in ribavirin še dodatnih 36 tednov, do skupnega trajanja zdravljenja 48 tednov.
Patients with diabetes mellitus: caution should be exercised when administering bexarotene in patients using insulin, agents enhancing insulin secretion (e.g. sulfonylureas), or insulin-sensitisers (e.g. thiazolidinediones).
Bolniki s sladkorno boleznijo (diabetes mellitus): Pri dajanju beksarotena bolnikom, ki uporabljajo inzulin, sredstva za izboljšanje izločanja inzulina (npr. sulfonil sečnine), ali inzulinske senzibilizatorje (npr. tiazolidinedion), je potrebna posebna previdnost.
Patients with diabetes or glucose intolerance should be monitored closely during somatropin therapy.
Bolnike s sladkorno boleznijo ali z moteno toleranco za glukozo je treba med zdravljenjem s somatropinom skrbno nadzirati.
Patients with diabetes who are breast-feeding may require adjustments in insulin dose, diet or both.
Pri doječih materah z diabetesom bo morda potrebna prilagoditev odmerka insulina, sprememba prehrane ali oboje.
Patients with diabetes who are breast-feeding may require adjustments in insulin dose, diet, or both.
Pri doječih materah z diabetesom bo morda potrebna prilagoditev odmerka insulina, sprememba prehrane ali oboje.
patients with diabetic ketoacidosis (high blood levels of acids called ‘ketones’) or diabetic pre-coma (a dangerous condition that can occur in diabetes);
bolnikih z diabetično ketoacidozo (visoke ravni kislin, imenovanih ketoni, v krvi) ali diabetično predkomo (nevarno stanje, ki se lahko pojavi pri sladkorni bolezni);
patients with diabetic ketoacidosis (high blood levels of acids called ‘ketones’) or diabetic pre-coma (a dangerous condition that can occur in diabetes);
bolnikih z diabetično ketoacidozo (visokimi ravnmi kislin, imenovanih ketoni, v krvi) ali diabetično predkomo (nevarnim stanjem, ki se lahko pojavi pri sladkorni bolezni);
patients with diabetic ketoacidosis or pre-coma (dangerous complications of diabetes),
bolnikih z diabetično ketoacidozo ali predkomo (nevarna zapleta, ki se lahko pojavita pri sladkorni bolezni);
Patients with diseases of the respiratory tract
Bolniki z boleznimi dihal
patients with diseases that could cause tissue hypoxia (reduced levels of oxygen in body tissues);
bolnikih z boleznimi, ki lahko povzročijo hipoksijo tkiv (zmanjšane ravni kisika v telesnih tkivih);
Patients with disturbances of bone and mineral metabolism
Bolniki z motnjami kosti in presnove mineralov
Patients with documented RET mutation (n=187)
Bolniki z dokazano mutacijo RET
Patients with Duchenne muscular dystrophy lack normal dystrophin, a protein found in muscles.
Bolniki z Duchennovo mišično distrofijo imajo pomanjkanje normalnega distrofina, beljakovine, ki je prisotna v mišicah.
Patients with Dupuytren’s contractures that adhere to the skin may be at higher risk of skin lesions as a result of the pharmacological effect of Xiapex and the finger extension procedure on the skin overlying the targeted cord.
Bolniki z Dupuytrenovimi kontrakturami, ki se držijo kože, imajo večje tveganje za kožne spremembe na koži, ki leži nad tarčnim vozličem, kot posledica farmakoloških učinkov zdravila Xiapex in postopka iztegovanja prsta.
Patients with dyspnoea at rest due to complications of advanced malignancy and co-morbidities may be at increased risk of pulmonary events.
Bolniki z dispnejo v mirovanju zaradi zapletov napredovale maligne bolezni in sočasnih bolezni imajo lahko večje tveganje za pljučne neželene dogodke.
Patients with each subtype of PsA were enrolled in the 3 studies, including symmetric polyarthritis (62.0%), asymmetric oligoarthritis (26.9%), distal interphalangeal (DIP) joint arthritis (6.2%), arthritis mutilans (2.7%), and predominant spondylitis (2.1%).
Bolnike z vsako podvrsto PsA so vključili v te 3 študije, vključno s simetričnim poliartritisom (62,0 %), asimetričnim oligoartritisom (26,9 %), artritisom distalnih interfalangealnih (DIP) sklepov (6,2 %), mutilirajočim artritisom (2,7 %) in predominantnim spondilitisom (2,1 %).
Patients with each subtype of PsA were enrolled in these studies, including polyarticular arthritis with no evidence of rheumatoid nodules, spondylitis with peripheral arthritis, asymmetric peripheral arthritis, distal interphalangeal involvement and arthritis mutilans.
V ti dve študiji so bili vključeni bolniki z vsemi podtipi psoriatičnega artritisa, vključno s poliartikularnim artritisom brez revmatoidnih vozličev, s spondilitisom s perifernim artritisom, z asimetričnim perfernim artritisom, s prizadetostjo distalnih interfalagealnih sklepov in z mutilirajočim artritisom.
Patients with Eastern Cooperative Oncology Group (ECOG) performance status at baseline of 2 experienced a higher incidence of serious infections compared to patients with ECOG performance status of < 2.
Incidenca resnih okužb je bila večja pri bolnikih z izhodiščnim stanjem zmogljivosti 2 po ECOG (Eastern Cooperative Oncology Group) kot pri bolnikih z izhodiščnim stanjem zmogljivosti < 2 po ECOG.
Patients with Eastern Cooperative Oncology Group (ECOG) performance status score ≥ 2 were excluded from the clinical trials of NSCLC (see sections 4.4 and 5.1).
Bolnike z oceno telesne zmogljivosti po lestvici ECOG (Eastern Cooperative Oncology Group) ≥ 2 so iz kliničnih preskušanj pri NSCLC izključili (glejte poglavji 4.4 in 5.1).
Patients with ECOG performance status at baseline of 2 experienced a higher incidence of serious infections compared to patients with ECOG performance status of < 2.
Incidenca resnih okužb je bila pri bolnikih z izhodiščnim stanjem zmogljivosti 2 po ECOG večja kot pri bolnikih s stanjem zmogljivosti < 2 po ECOG.
Patients with ECOG score ≥2 were excluded from the pivotal studies in all indications, therefore the safety and efficacy of Cyramza in this patient population is unknown.
Bolniki z oceno ECOG ≥ 2 so bili izključeni iz ključnih študij za vse indikacije, zato varnost in učinkovitost zdravila Cyramza v tej populaciji bolnikov nista znani.
Patients with eGFR 45 mL/min/1.73 m2 to < 60 mL/min/1.73 m2
Bolniki z ocenjeno glomerulno filtracijo od 45 ml/min/1,73 m2 do < 60 ml/min/1,73 m2
Patients with eGFR improvement
Bolniki z izboljšanjem eGFR
Patients with EGFR or ALK positive tumour mutations should also have received approved therapy for these mutations prior to receiving KEYTRUDA.
Bolniki s pozitivnimi mutacijami EGFR ali ALK so pred prejemom zdravila KEYTRUDA morali prejeti tudi zdravljenje, odobreno v primeru teh mutacij.
Patients with elevated bilirubin must not be treated with trabectedin (see section 4.2).
Bolnikov s povišano ravnjo bilirubina ni dovoljeno zdraviti s trabektedinom (glejte poglavje 4.2).
Patients with elevated bilirubin must not be treated with Yondelis (see section 4.4).
Bolnikov s povišano ravnjo bilirubina ni dovoljeno zdraviti z zdravilom Yondelis (glejte poglavje 4.4).
Patients with elevated biomarkers (troponin or CK-MB) and without a prior stroke/TIA constituted 80 % of the study population.
Bolniki s povečanimi vrednostmi biokemičnih označevalcev (troponin ali CK-MB) in brez predhodne možganske kapi/prehodnega ishemičnega napada (TIA) predstavljajo 80 % študijske populacije.
Patients with elevated ferritin levels receiving intravenous iron may require a reduction in dose or discontinuation of intravenous iron therapy.
Pri bolnikih s povišanimi ravnmi feritina, ki prejemajo intravensko železo, bo morda treba zmanjšati odmerek ali prekiniti intravensko zdravljenje z železom.
Patients with elevated liver enzymes (ALT/AST > 2 x ULN) or total bilirubin ≥ 1.5 x ULN were excluded in clinical trials.
Bolnike z zvišanimi jetrnimi encimi (ALT/AST >2 x ULN; ULN=upper level of normal – zgornja meja normalnih vrednosti) ali celotnim bilirubinom ≥1,5 x ULN so izključili iz kliničnih preskušanj.
Patients with elevated liver enzymes > 2 ULN were excluded from the main trials.
Bolnike s povečanimi jetrnimi encimi na > 2 ULN so izključili iz glavnih preskušanj.
Patients with elevated liver enzymes > 2 ULN were excluded in the main trials.
Bolnike s povečanimi jetrnimi encimi na > 2 ULN so izključili iz glavnih preskušanj.
Patients with elevated liver enzymes > 2 upper limit of normal (ULN) were excluded in clinical trials investigating the VTE prevention following elective hip or knee replacement surgery.
Bolnike s povečanimi jetrnimi encimi na več kot 2-kratno zgornjo mejo normalnih vrednosti (ULN) so iz kliničnih preskušanj v katerih so proučevali preprečevanje VTE po operativni vstavitvi umetnega kolka izključili.
Patients with elevated liver enzymes > 2 upper limit of normal (ULN) were excluded in clinical trials investigating the VTE prevention following elective hip or knee replacement surgery.
Bolnike s povečanimi jetrnimi encimi na več kot 2-kratno zgornjo mejo normalnih vrednosti (ULN) so iz kliničnih preskušanj, v katerih so proučevali preprečevanje VTE po operativni vstavitvi umetnega kolka ali kolena.
Patients with elevated liver enzymes > 2 upper limit of normal (ULN) were excluded in the main trials
Bolnike s povečanimi jetrnimi encimi na več kot 2-kratno zgornjo mejo normalnih vrednosti (ULN) so izključili iz glavnih preskušanj.
Patients with elevated liver enzymes > 2 upper limit of normal (ULN) were excluded inthe main trials
Bolnike s povečanimi jetrnimi encimi na več kot 2-kratno zgornjo mejo normalnih vrednosti (ULN) so izključili iz glavnih preskušanj.